Definition, Diagnosis, and Management of Post‑Acute Sequelae of SARS‑CoV‑2 Infection (PASC)

Definition & Timeline

• The Centers for Disease Control and Prevention (CDC) defines PASC as the presence of symptoms ≥ 4 weeks after acute COVID‑19 infection. 1
• The World Health Organization (WHO) and UK National Institute for Health and Care Excellence (NICE) adopt a more conservative definition, requiring symptoms to persist ≥ 12 weeks (3 months) and to last at least 2 months. [2][1]3
• Patients may develop PASC even when the acute infection was asymptomatic. [1][4]3

Common Clinical Manifestations

General (most frequent) symptoms

• Fatigue and breathlessness are the two most common manifestations of PASC. 2
• Cognitive impairment (“brain fog”) affects ≈ 16 % of patients at 2 months and rises to ≈ 26 % at 12 months after infection. 5
• Sleep disturbances/insomnia occur in ≈ 22–44 % of individuals with PASC. 6
• Chest pain and palpitations are frequently reported cardiovascular complaints. 7
• Postural tachycardia (POTS) is characterized by a heart‑rate increase > 30 bpm (often > 120 bpm) on standing. 8

Secondary manifestations

• Musculoskeletal pain or spasms are common somatic complaints. 9
• Cough may persist beyond the acute phase. 10
• Hair loss tends to appear later, being more common at ≈ 1 year than at 2 months post‑infection. 11

Cardiovascular manifestations

• The American College of Cardiology (ACC) distinguishes PASC‑CVD (identifiable cardiovascular disease) from PASC‑CVS (cardiovascular symptoms without objective findings). [9][1]10

PASC‑CVD (identifiable disease)

All above are reported sequelae of PASC in ACC literature. [8][12]

PASC‑CVS (symptoms without objective disease)

• Exercise intolerance with tachycardia (often meeting POTS criteria). 7
• Chest pain without evidence of ischemia on standard cardiac testing. 10
• Dyspnea despite normal structural cardiac and pulmonary studies. 8

Neurological manifestations

• Neurovascular events (ischemic stroke, hemorrhagic stroke, cerebral venous thrombosis) are recognized complications of PASC. 12
• Myalgic encephalomyelitis / chronic fatigue syndrome may develop after COVID‑19. 12
• Cognitive impairment can persist for ≥ 2 years in a subset of patients. 5

Risk Factors for Developing PASC

• Older age increases the likelihood of long‑COVID symptoms. 7
• Pre‑existing medical conditions (e.g., cardiovascular disease, diabetes) are associated with higher risk. 12
• Greater number of acute‑phase symptoms predicts subsequent PASC. 9
• Lack of COVID‑19 vaccination prior to infection is a modifiable risk factor. 6
• Infection with pre‑Omicron SARS‑CoV‑2 variants carries higher risk than later variants. 6
• Young, previously healthy individuals with mild acute illness can also develop PASC, underscoring that severity of the initial infection is not the sole determinant. 1

Clinical Evaluation Approach

Initial Assessment

• Any patient with symptoms persisting ≥ 4 weeks after acute COVID‑19 should receive an initial consultation (in‑person, video, or telephone) based on shared decision‑making. 2
• Key history elements: severity of the acute infection (hospitalization/ICU), timeline of symptom onset, impact on work/education/activities of daily living, and presence of fever, chest pain, dyspnea, or gastrointestinal symptoms that may suggest a hyperinflammatory state. [9][11][10][1]
• Physical exam priorities: orthostatic vital signs (supine & standing HR/BP after 5–10 min), cardiovascular and pulmonary examinations, and a brief neurological/cognitive screen. [2][12]6

Diagnostic Testing Strategy

For cardiovascular symptoms

• Initial tests: 12‑lead ECG, transthoracic echocardiography (shows diastolic dysfunction in ≈ 55–60 % of recovering patients; LV systolic dysfunction is rare), basic labs (troponin, BNP, inflammatory markers), and orthostatic vitals for POTS evaluation. [7][10]8
• Advanced imaging (when initial work‑up is unrevealing): cardiac MRI with late gadolinium enhancement (identifies myocardial inflammation in ≈ 17 % of symptomatic patients) and FDG‑PET (correlates with CMR abnormalities and inflammatory markers). [10][8]
• Functional testing: pulmonary function tests and cardiopulmonary exercise testing to characterize exercise intolerance. [8][10]
• Important caveat: Standard cardiac testing may be normal despite debilitating symptoms; normal results do not exclude PASC. [1][10]

For neurological symptoms

• Cognitive screening tools should be administered; neuroimaging is reserved for focal neurological deficits. [10][5]
• Evaluate for thromboembolic complications if acute neurological changes occur. 12

Management Strategies

Overall Framework

• Management is individualized according to whether identifiable cardiovascular disease (PASC‑CVD) is present or symptoms are unexplained (PASC‑CVS). [9][1]8

PASC‑CVD (identifiable disease)

• Myocarditis – treat with guideline‑directed heart‑failure therapy; avoid exercise during active inflammation. 7
• Ischemic heart disease – antiplatelet agents, statins, and revascularization as indicated. 12
• Arrhythmias – rate or rhythm control per standard ACC protocols. 8
• Thromboembolic disease – anticoagulation according to established ACC recommendations. 12

PASC‑CVS and General Symptom Management

• Exercise – contraindicated in patients with brain fog or post‑exertional malaise; ≈ 75 % experience worsening with activity, < 1 % improve. 5
• Cognitive & fatigue management – pacing strategies adapted from ME/CFS, low‑dose aripiprazole for fatigue/brain fog, and low‑dose naltrexone for pain/fatigue. 5
• POTS/autonomic dysfunction – β‑blockers, pyridostigmine, fludrocortisone, or midodrine; increase dietary salt and fluid; consider IV saline or compression stockings. 5
• Sleep disturbances – implement sleep‑hygiene measures and, if needed, pharmacologic therapy. [6][5]
• Emerging therapies – early Paxlovid reduces long‑COVID incidence by ≈ 25 %; case reports suggest benefit of intravenous immunoglobulin, triple anticoagulant regimens, and the peptide BC007 for auto‑antibody neutralization. 5

Multidisciplinary Care Coordination

• A patient‑centered, multidisciplinary team is recommended, with the primary‑care clinician serving as the care‑coordination hub. Team members include pulmonologists, cardiologists, neurologists, rheumatologists, psychiatrists, infectious‑disease specialists, social workers, psychologists, and physical therapists. [1][4][7][3]

Prognosis & Follow‑up

• Long COVID affects roughly 10–20 % of all infected individuals, with cumulative prevalence ranging from 9 % to 63 % depending on case definition. (Prevalence figures derived from epidemiologic studies.)
• Symptoms may persist months to years; cognitive impairment and sleep disturbances have been documented ≥ 2 years after infection. [5][6]
• Ongoing monitoring should focus on functional status, mental health, and organ‑specific sequelae, with referral to specialty care when new or worsening manifestations arise.

Long COVID: Definition, Epidemiology, Clinical Features, Risk Factors, Evaluation, Management, and Prognosis (Cited Evidence)

Definition and Timeline

• Long COVID is defined as the presence of one or more symptoms that persist or relapse for more than 12 weeks after the acute COVID‑19 diagnosis, without an alternative explanation. 13
• The U.S. CDC adopts a more liberal threshold of 4 weeks, whereas the WHO and European guidelines require symptoms lasting at least 12 weeks and persisting for a minimum of 2 months. 13
• The condition can affect any individual who had COVID‑19, irrespective of the severity or symptomatology of the acute infection. 13

Epidemiology (Prevalence of Key Symptoms)

• Fatigue is the most common manifestation, reported in 31 %–58 % of patients with long COVID. 13
• Dyspnea (shortness of breath) occurs in 24 %–40 % of affected individuals. 13
• Cognitive impairment (“brain fog”) is present in 12 %–35 % initially, rising to approximately 16 % at 2 months and 26 % at 12 months post‑infection. 13
• Sleep disturbances and insomnia affect 11 %–44 % of patients, often co‑existing with fatigue and cognitive symptoms. 13
• Musculoskeletal pain (myalgia, joint pain, muscle spasms) is reported by 9 %–19 % of patients. 13
• Anosmia/dysgeusia (loss of smell/taste) persists in 10 %–22 % of individuals beyond the acute phase. 13
• Persistent cough is noted in 7 %–29 % of recovering patients. 13
• Chest pain is reported by 6 %–17 % of individuals, with or without identifiable cardiac pathology. 13

Risk Factors for Developing Long COVID

• Female sex confers an estimated two‑fold increased risk (odds ratio 1.3–5) compared with males. 13
• Severe acute COVID‑19 (requiring hospitalization or ICU care) is the strongest predictor, particularly for fatigue. 13
• Older age is associated with a higher likelihood of persistent symptoms. 13
• Pre‑existing medical conditions (e.g., cardiovascular disease, diabetes, obesity) are linked to increased risk, although findings are heterogeneous. 13

Clinical Evaluation Approach

• Long COVID is a diagnosis of exclusion; clinicians must first rule out other serious conditions such as malignancy, thromboembolic events, myocarditis, or encephalitis. 13
• For patients with persistent respiratory symptoms, routine chest imaging and pulmonary function testing are recommended at 3 months after acute infection. 14
• Additional diagnostic tests should be performed primarily to exclude alternative diagnoses, guided by the specific symptom profile. 14
• Physical and respiratory rehabilitation should be initiated only after ruling out post‑exertional malaise to avoid symptom exacerbation. 14

Management Strategies

• No high‑quality evidence‑based interventions exist for long COVID; current recommendations are conditional and based on limited data. [14][15]
• Multidisciplinary care is advised, with the primary‑care clinician coordinating input from specialists (e.g., pulmonology, cardiology, neurology). Pulmonology involvement is specifically highlighted for persistent respiratory manifestations. 14

Prognosis and Long‑Term Outlook

• 57 % of patients with symptoms persisting beyond 12 weeks report a decreased quality of life. 13
• Long‑COVID symptoms have been documented to persist for 12 months or longer after the acute illness. 13